Ponce De Leon Foundation Announces Grant Awards
BRONX, N.Y., Jan. 29, 2024 (GLOBE NEWSWIRE) — The Board of Directors of the Ponce De Leon Foundation is pleased […]
AMERANT BANK PROVIDES FINANCING TO FRESCO RETAIL GROUP, LLC FOR THE ACQUISITION OF FRESCO Y MÁS OPERATIONS AND LOCATIONS
CORAL GABLES, Fla., Jan. 29, 2024 (GLOBE NEWSWIRE) — Amerant Bank, the largest community bank headquartered in Florida, led the […]
Penns Woods Bancorp, Inc. Reports Fourth Quarter and Year Ended 2023 Earnings
WILLIAMSPORT, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) — Penns Woods Bancorp, Inc. (NASDAQ: PWOD) Penns Woods Bancorp, Inc. achieved net income of […]
Great Southern Bancorp, Inc. to Hold 35th Annual Meeting of Stockholders
SPRINGFIELD, Mo., Jan. 29, 2024 (GLOBE NEWSWIRE) — Great Southern Bancorp, Inc. (NASDAQ:GSBC), the holding company for Great Southern Bank, […]
Santa.com Wraps Up 2023 Christmas Season With Gains Across Several Key Visitor Metrics
Year-Over-Year Growth Positions Grom’s Digital Holiday Platform for Share of Record $222 Billion Domestic E-commerce Holiday Sales BOCA RATON, Fla., […]
Spectral Submits Application for UKCA Mark Classification
DALLAS, Jan. 29, 2024 (GLOBE NEWSWIRE) — Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (NASD: MDAI; MDAIW) […]
J-Long Group Limited Announces Closing of its Initial Public Offering
HONG KONG, Jan. 29, 2024 (GLOBE NEWSWIRE) — J-Long Group Limited (Nasdaq: JL) (the “Company” or “J-Long”), an established distributor […]
Freshworks Announces Strategic Collaboration Agreement with AWS to Increase the Reach of its AI-boosted Software-as-a-Service
SAN MATEO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) — Freshworks Inc. (NASDAQ: FRSH) announced today that it has signed a […]
The Mullen THREE, Class 3 EV Truck Now CARB Certified and Ready for Sale in All CARB States and District of Columbia
Certification opens the Mullen THREE EV truck with a suggested MSRP of $68,500.00 to important state incentive programs; including opportunity […]
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in […]
